Analysis of KOBE Biomedical Innovation Cluster based on Michael Porter Strategy

Abstract

Kobe city at Hyogo prefecture in Japan suffered the Kobe earthquake in 1995, which caused economic losses of 6.9 trillion yen and human casualties of 4,600 within Kobe city. Kobe Biomedical Cluster was put RD 2. Clinical trial support; 3. Clinical application for regeneration medical technology. Issues are the lack of trust in RIKEN due to the IPS cell affair in Japan, in which one researcher plagiarized research of STAP cells. Riken had to change its name. It was unknown to healthy adults. The degree of community penetration of K supercomputer is low on a world scale and even less for engineers, which can utilize K supercomputer. Then, this research applies them into Diamond Flame of Michel Porter (Cho) and the BCG model and Product Market Matrix (Iizawa), which find improvement strategies in the big picture. Result of Product Market Matrix (Iizawa) is as follow. KBIC was located at diversification because the new advanced technology is unique and regeneration medicine is an outstanding market. Result of BCG model (Iizawa) is that market growth rate is high because people have easy access to related medical agencies within 5 minutes. KBIC wasn't known outside of healthcare practitioners. KBIC should shift its market worldwide. Its methods are to introduce medical tourism and information for coming through competitive society.